Aytu Biopharma Q1 2026 Results: Net Loss of $3.88M
Aytu BioPharma reported significant warrant reclassifications from liability to equity following amendments in March 2026. The company maintains a $3.8 million Employee Retention Credit accrual and continues to manage debt through an Eclipse Business Capital loan agreement, while focusing on its ADHD and Pediatric portfolios.
- Key figure
- Net loss $3.88M